title: Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
abstract: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research.
  
  
  
  ClinicalTrials.gov: NCT00692770 . Registered 5 June 2008. This study has been completed.
authors.affiliation: Department of Hepatology, Beaujon University Hospital, 100 boulevard du Général Leclerc, Clichy, 92110, France. mohamed.bouattour@aphp.fr.
authors.forename: Mohamed
authors.identifier: 0000-0002-3919-4135
authors.initials: M
authors.lastname: Bouattour
authors.affiliation: Surgery and Liver Transplant Department, Beaujon University Hospital, Clichy, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Soubrane
authors.affiliation: AFR-Oncology, Boulogne-Billancourt, France.
authors.forename: Armand
authors.initials: A
authors.lastname: de Gramont
authors.affiliation: Medical Oncology Department, Beaujon University Hospital, Clichy, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Faivre
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation / Q000009:adverse effects / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D006498:Hepatectomy / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
keywords: Antiangiogenic agents; Clinical trials; Hepatectomy; Local ablation